Nkarta IncNKTX
Price$2.56

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$104.1MTTM through 30 Jun 2026
Free Cash Flow -$93.9MTTM through 30 Jun 2026

Margins

Current

Returns

-9.7%ROE
-30.8%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio7.98x
Net Debt-$266.7Mnet cash position
Cash & Equivalents$25M

Quality Metrics

Altman Z-Score-2.17
Piotroski F-Score1 / 9
Earnings-Beat Rate66.7%

Multi-Year Trend

Revenue
'19'24'25
FY2025: $0
Diluted EPS-$1.59TTM
'21'22'23'24'25
FY2025: $-1.41

Dividend

No dividend

Capital Allocation

R&D Spend$99.5M

Segment Performance

SegmentRevenueYoYOutlook
NK cell therapies$0
View details

Initial clinical data from Ntrust-1 and Ntrust-2 are planned for presentation at a medical conference in 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.